Ohr Pharmaceutical (Nasdaq:OHRP), a pharmaceutical company developing therapies for ophthalmic diseases, today reported financial results and operating highlights for its fiscal first quarter ended December 31, 2017. As quoted in the press release: “We recently announced top-line results from the MAKO study evaluating the efficacy and safety of topically administered squalamine in combination with monthly …

As quoted in the press release:

“We recently announced top-line results from the MAKO study evaluating the efficacy and safety of topically administered squalamine in combination with monthly Lucentis^® injections for the treatment of wet-AMD, which did not meet its primary efficacy endpoint,” said Dr. Jason Slakter, chief executive officer of Ohr Pharmaceutical. “Based on these results, we have discontinued development of squalamine, taken measures to preserve cash and are evaluating strategic alternatives to maximize shareholder value.”

Click here to read the full press release.